Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MedtideFRA:FQ2 -6.03%31 OCF Margin % is 26.68% as of Dec. 2025, which is 31% below its 10-year median of 38.42. GuruFocus rates FRA:FQ2 with a GF Score™ of 31/100. Among 961 Biotechnology companies, Medtide ranks better than 95.84% on this metric.
The historical data trend for Medtide's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:FQ2 vs VRTX, REGN, MRNA: OCF Margin % Comparison
For the Biotechnology subindustry, Medtide's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medtide OCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Medtide's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Medtide's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medtide (FRA:FQ2) has a OCF Margin % of 26.68% as of Dec. 2025. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Medtide and its competitors. This is 31% below median its historical median of 38.42. Over the past decade, Medtide's OCF Margin % has ranged from 26.23 to 48.42. According to the industry distribution chart, Medtide ranks #40 out of 961 companies in the Biotechnology industry, placing it in the top 4.2%.
Is Medtide's OCF Margin % too high?
Medtide's current OCF Margin % of 26.68% is 31% below median its 10-year median of 38.42. Over the past 10 years, this metric has ranged from a low of 26.23 to a high of 48.42. Based on the distribution chart, Medtide ranks #40 out of 961 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Medtide has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Medtide's OCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Medtide ranks #40 out of 961 companies for OCF Margin %. This places Medtide in the top 4% of its industry — outperforming the majority of peers. Historically, Medtide's own OCF Margin % has ranged from 26.23 to 48.42 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Medtide and its competitors. Medtide's current OCF Margin % is 26.68%, which is 31% below median its own 10-year median of 38.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medtide stock overvalued right now?
Medtide (FRA:FQ2) has a current OCF Margin % of 26.68%. The current OCF Margin % is 26.68%, which is 31% below median its 10-year median of 38.42. Medtide's overall GF Score™ is 31/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Medtide (FRA:FQ2), the current OCF Margin % is 26.68% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Medtide Inc offers full-cycle services ranging from early-stage discovery, preclinical research and clinical development to commercial-stage production. It mainly provide (i) CRO services, namely peptide NCE discovery synthesis; and (ii) CDMO services, namely peptide CMC development and commercial manufacturing. Its services focus on providing customers with APIs rather than drug products. Geographically, the company generates majority of its revenue from USA.
31GF Score
Get the complete analysis for FRA:FQ2
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:FQ2 has been successfully added to your 
